Renal cell carcinoma (RCC) is a prevalent malignancy with a steadily increasing incidence. This study examined the association between clinical and pathological factors and RCC patient survival ...

Prostate cancer patients with biochemical recurrence (BCR) face a decision of whether to start salvage therapy (ST), which may reduce the probability of metastatic progression at the cost of side ...

Kenshiro Shiraishi reports 10-year findings from MRI-guided salvage radiotherapy following radical prostatectomy. In a prospective single-arm trial with 40 patients utilizing 3-Tesla multiparametric ...

Many older adults with cancer have at least one comorbidity. Type II diabetes mellitus (T2DM) is a common comorbidity among patients with prostate cancer (PC) and represents an important consideration ...

Michael Ong describes the TRIPLE-SWITCH trial design, a phase 3 study randomizing patients with metastatic hormone-sensitive prostate cancer and PSA of 0.2 or above at six to twelve months of ADT plus ...

Despite Bacillus Calmette-Guerin (BCG) remaining the standard of care for high-risk non-muscle-invasive bladder cancer (HR-NMIBC), novel combination strategies are being actively investigated.

Introduction: Cryoablation is an established nephron-sparing option for small renal masses, particularly in patients unsuitable for surgery. However, definitive histopathological assessment ...

The publication of our phase 3 trial of aglatimagene besadenovec in The Lancet Oncology represents an important milestone in the treatment of localized prostate cancer. While the primary publication ...

(UroToday.com) The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was host to a kidney and bladder cancers poster session. Dr. Robert Motzer presented the final analysis of the ...

(UroToday.com) The 2026 ASCO annual meeting featured an oral abstract kidney cancer session and a presentation by Dr. Junru Chen discussing a prospective, multi-center, phase Ib/II trial of first line ...

Stereotactic body radiotherapy (SBRT) delivered on an MRI-guided linear accelerator (MR-linac) enables highly conformal prostate cancer irradiation. The DESTINATION 2 trial is a federated, randomised ...

Radiopharmaceutical therapy with 225Ac-labeled prostate-specific membrane antigen (225Ac-PSMA) has shown promising results in patients with metastatic castration-resistant prostate cancer (mCRPC). To ...